SLC5A2 and type 2 diabetes mellitus: Although the majority of the included RCTs involved T2DM patients, two studies included heart failure patients,7, 118and one involved chronic kidney disease patients.8Another meta-analysis by Wang et al.34included 14 RCTs3, 7, 8, 113, 115, 117, 118, 119, 120, 121, 122, 123, 124and similarly found no association between SGLT2 inhibitors (vs. placebo) and DVT risk (80/48,446 vs. 86/41,886; RR 0.80, 95% CI 0.58–1.11), with trials involving patients with T2DM, heart failure, or chronic kidney disease.